言語を選択

HLA-A*0201 & B2M & WT-1

お問い合わせ

HLA-A*0201 & B2M & WT-1バックグランド

Wilms tumor gene 1 (WT1), is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies.

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Rocatinlimab	KHK-4083; AMG-451	Phase 3 Clinical	Kyowa Hakko Kirin Co Ltd, Amgen Inc	Abdominal Pain; Inflammatory Bowel Diseases; Digestive System Diseases; Gastrointestinal Diseases; Autoimmune Diseases; Colitis; Asthma; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases	詳細
Ivuxolimab	PF-8600; PF-04518600	Phase 3 Clinical	Pfizer Inc	Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung	詳細
INBRX-106	INBRX-106; ES-102; ES102	Phase 3 Clinical	Inhibrx	Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung	詳細
GSK3174998	GSK3174998; GSK 3174998; GSK-3174998	Phase 2 Clinical	Glaxosmithkline Plc	Neoplasms; Multiple Myeloma	詳細
Telazorlimab	GBR-830; ISB-830	Phase 2 Clinical	Glenmark Pharmaceuticals Ltd	Dermatitis, Atopic	詳細
BMS-986178	BMS-986178	Phase 2 Clinical	Bristol-Myers Squibb Company	Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell	詳細
SAR-442970	SAR-442970	Phase 2 Clinical	Sanofi	Inflammation; Hidradenitis Suppurativa	詳細
IMG-007	IMG-007	Phase 2 Clinical		Alopecia Areata; Dermatitis, Atopic	詳細
BAT-6026	BAT-6026	Phase 2 Clinical	Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd, Bio-Thera Solutions Ltd	Solid tumours; Autoimmune Diseases; Dermatitis, Atopic	詳細
BGB-A445	BGB-A445	Phase 2 Clinical		Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma	詳細
Recombinant human anti-OX40 monoclonal antibody (Livzon Group)		Phase 1 Clinical	Livzon Pharmaceutical Group Inc	Neoplasms	詳細
SL-279252	TAK-252; SL-279252	Phase 1 Clinical	Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc	Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma	詳細
FS-120	FS-120	Phase 1 Clinical	F-Star	Neoplasms; Neoplasm Metastasis	詳細
Cudarolimab	IBI-101	Phase 1 Clinical	Innovent Biologics(Suzhou) Co Ltd	Solid tumours; Neoplasms	詳細
ATOR-1015	ADC-1015; ATOR-1015	Phase 1 Clinical	Alligator Bioscience Ab	Solid tumours; Neoplasms	詳細
Revdofilimab	ABBV-368; PR-1628103	Phase 1 Clinical	Abbvie Inc	Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung	詳細
SHR-1806	SHR-1806	Phase 1 Clinical		Neoplasms	詳細
Tavolimab	MEDI-0562	Phase 1 Clinical	Medimmune	Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma	詳細
Vonlerolizumab	RG-7888; MOXR-0916; RO-7021608	Phase 1 Clinical	Genentech Inc	Neoplasms; Carcinoma, Transitional Cell	詳細
EMB-09	EMB-09	Phase 1 Clinical	Shanghai Epimab Biotherapeutics, Inc	Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Hepatitis B, Chronic; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular	詳細
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma)	YH-002	Phase 1 Clinical	Eucure Pharmaceutical Technology (Beijing) Co Ltd	Solid tumours	詳細
HFB-3010(HiFiBiO Therapeutics)	HFB-3010; HFB-301001	Phase 1 Clinical	HiFiBiO Therapeutics	Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Melanoma	詳細
HLX-51	HLX-51	Phase 1 Clinical		Solid tumours; Lymphoma	詳細
KN-052	KN-052	Phase 1 Clinical	Suzhou Alphamab Co Ltd	Solid tumours	詳細
MEDI-6469	MEDI-6469; AGX-051	Phase 1 Clinical	Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services	Liver Neoplasms; Head and Neck Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis	詳細